Air pollutant–mediated disruption of sinonasal epithelial cell barrier function is reversed by activation of the Nrf2 pathway - 18/04/17

Disclosure of potential conflict of interest: N. R. London holds patents for composition and methods for treating pathologic angiogenesis and endothelial hyperpermeability and has stock options with Navigen Pharmaceuticals, which are currently of no value. A. M. Rule has received support from the National Institutes of Health (grant no. K23ES020859). The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 138 - N° 6
P. 1736 - décembre 2016 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?